Ren Danyang, Chen Jun, Yu Meirong, Yi Chenggang, Hu Xueqing, Deng Junjie, Guo Songxue
Department of Plastic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Department of Plastic Surgery, Linhai Branch, The Second Affiliated Hospital, Zhejiang University School of Medicine, Taizhou, Zhejiang, China.
J Tissue Eng. 2024 May 30;15:20417314241254508. doi: 10.1177/20417314241254508. eCollection 2024 Jan-Dec.
Vascularized composite allotransplantation (VCA), which can effectively improve quality of life, is a promising therapy for repair and reconstruction after face or body trauma. However, intractable issues are associated with VCA, such as the inevitable multiple immunogenicities of different tissues that cause severe rejection, the limited protocols available for clinical application, and the shortage of donor sources. The existing regimens used to extend the survival of patients receiving VCAs and suppress rejection are generally the lifelong application of immunosuppressive drugs, which have side effects. Consequently, studies aiming at tissue engineering methods for VCA have become a topic. In this review, we summarize the emerging therapeutic strategies for tissue engineering aimed to prolong the survival time of VCA grafts, delay the rejection and promote prevascularization and tissue regeneration to provide new ideas for future research on VCA treatment.
血管化复合组织异体移植（VCA）能够有效改善生活质量，是面部或身体创伤后修复与重建的一种很有前景的治疗方法。然而，VCA也存在一些棘手的问题，比如不同组织不可避免地具有多种免疫原性，会导致严重的排斥反应，临床应用的方案有限，以及供体来源短缺。目前用于延长接受VCA患者的生存期并抑制排斥反应的现有方案通常是终身应用免疫抑制药物，而这些药物有副作用。因此，针对VCA的组织工程方法的研究已成为一个热门话题。在这篇综述中，我们总结了旨在延长VCA移植物存活时间、延缓排斥反应并促进血管生成和组织再生的组织工程新兴治疗策略，以为未来VCA治疗的研究提供新思路。
